130 related articles for article (PubMed ID: 21903506)
1. [Immunoglobulin A nephropaty: clinical practice guidelines].
Fayad A; Robaina Sindin J; Calvo Abeucci M; Trimarchi H; Vázquez V
Medicina (B Aires); 2011; 71 Suppl 2():1-26. PubMed ID: 21903506
[TBL] [Abstract][Full Text] [Related]
2. Modulating the progression in IgA nephropathy.
Chan JC; Trachtman H
Nephron Clin Pract; 2006; 104(1):c61-8. PubMed ID: 16741372
[TBL] [Abstract][Full Text] [Related]
3. Treatment of IgA nephropathy: an update.
Rosselli JL; Thacker SM; Karpinski JP; Petkewicz KA
Ann Pharmacother; 2011 Oct; 45(10):1284-96. PubMed ID: 21954446
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin A nephropathy: fish oils and beyond.
Feehally J
Curr Opin Nephrol Hypertens; 1996 Sep; 5(5):442-6. PubMed ID: 8937814
[TBL] [Abstract][Full Text] [Related]
5. Non-immunosuppressive treatment for IgA nephropathy.
Reid S; Cawthon PM; Craig JC; Samuels JA; Molony DA; Strippoli GF
Cochrane Database Syst Rev; 2011 Mar; (3):CD003962. PubMed ID: 21412884
[TBL] [Abstract][Full Text] [Related]
6. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
[TBL] [Abstract][Full Text] [Related]
7. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.
Locatelli F; Vecchio LD; Pozzi C
Nat Clin Pract Nephrol; 2006 Jan; 2(1):24-31. PubMed ID: 16932386
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
Soleymanian T; Najafi I; Salimi BH; Broomand B
Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
[TBL] [Abstract][Full Text] [Related]
10. Treatment of immunoglobulin A nephropathy.
Schiele J; Nowack R; Julian BA; van der Woude FJ
Ann Med Interne (Paris); 1999 Feb; 150(2):127-36. PubMed ID: 10392261
[TBL] [Abstract][Full Text] [Related]
11. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evidence of therapy of IgA nephropathy].
Gan WH; Zhang AQ; Ding GX; Gong J
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Apr; 9(2):101-3. PubMed ID: 17448301
[No Abstract] [Full Text] [Related]
13. [Management of IgA nephropathy].
Amoroso L; De Sanctis L; Cappelli P; Di Vito R; Sirolli V; Bonomini M
G Ital Nefrol; 2011; 28(6):622-32. PubMed ID: 22167613
[TBL] [Abstract][Full Text] [Related]
14. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
15. Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patients.
Galindo-Ocaña J; Bernabeu-Wittel M; Formiga F; Fuertes-Martín A; Barón-Franco B; Murcia-Zaragoza JM; Moreno-Gaviño L; Ollero-Baturone M;
Eur J Intern Med; 2012 Mar; 23(2):179-84. PubMed ID: 22284251
[TBL] [Abstract][Full Text] [Related]
16. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
17. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM
Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
[TBL] [Abstract][Full Text] [Related]
18. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
19. The treatment of IgA nephropathy: status at the end of the millenium.
Glassock RJ
J Nephrol; 1999; 12(5):288-96. PubMed ID: 10630691
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T; Pohl M; Misselwitz J; John U
Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
